

Investment Accelerator Fund

The Investment Accelerator Fund (IAF) provides up to \$500,000 in seed funding to qualified emerging companies in Ontario. As a critical component of the Ontario Network of Excellence (ONE), the IAF supports the launch and development of innovative companies in Ontario's priority sectors of advanced materials and manufacturing, information technology, cleantech and life sciences. By supporting these companies, the IAF helps create high-value jobs that contribute to Ontario's innovation agenda. The IAF is funded by the Government of Ontario and delivered by MaRS.

The IAF is funded by the Government of Ontario and delivered by MaRS. For more information, please visit www.marsdd.com/iaf.

New IAF portfolio companies include:

Locationary Inc.



Locationary is engaging and empowering people around the world to collect, manage and enhance local business place data for the benefit of individuals, organizations and businesses. The company has created a sophisticated cloud-based local data management system that helps publishers reduce the costs of managing and enhancing their local data. Locationary offers a free platform, specialized tools and access to data updates from locals, business owners and other publishers. The company's active global community of editors and developers are financially rewarded for adding and verifying data and performing services for companies who use the platform.

www.locationary.com

GridCentric Inc.



GridCentric has developed next generation virtualization technology that dramatically reduces the amount of server memory required to support large-scale Virtual Desktop Infrastructure (VDI) implementations.

www.gridcentric.com

Karos Health



Karos Health is creating an exchange network to improve electronic ordering and results distribution of diagnostic imaging tests between client hospitals, imaging centers and radiology reading services.

www.karoshealth.com

Temporal Power



Temporal Power develops and manufactures flywheel electricity storage systems that deliver high power and energy capacity coupled with low standby losses and heavy-duty cycle capability. The company's breakthrough technology enables utilities, generators and industrial customers to realize the benefits of large-scale energy storage with a low cost, high performance solution.

www.temporal-power.com



Investment Accelerator Fund-Life Sciences

The Investment Accelerator Fund-Life Sciences (IAF-LS) helps accelerate the growth of life sciences companies in Ontario. The fund invests up to \$1,000,000 in seed and later stage financing in companies that have the potential to be global leaders in their field and provide sustainable economic benefits to Ontario. Funded by the Government of Ontario, the fund is a \$7 million program that helps innovative life sciences companies turn their discoveries into new products and services that meet patient needs.

The IAF-LS is delivered by MaRS. For more information, please visit www.marsdd.com/iaf-lifesciences.

New IAF-LS portfolio companies include:



Xagenic Inc.

Xagenic Inc. is commercializing a low cost, chip-based diagnostic testing system that employs nanotechnology-based microelectrodes. This technology, invented at the University of Toronto, is being developed to address a large clinical unmet need: rapid, on-demand, sample-to-answer detection of pathogens in less than 30 minutes.

www.xagenic.com



Profound Medical Inc.

Profound is a medical device company that is commercializing a MRI-guided thermal ultrasound device for the most accurate and precise treatment of localized prostate cancer. The MRI-guided trans-urethral ultrasound device allows for incomparable treatment speed, accuracy and precision. This is all achieved in an outpatient setting, providing faster patient recovery coupled with minimal residency time in the hospital setting.

www.profoundmedical.com



Cytochroma

Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The company specializes in developing new therapies that are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.

www.cytochroma.com



Trillium Therapeutics Inc.

Trillium is developing a new and innovative treatment of interstitial cystitis (IC), a chronic, debilitating and poorly treated bladder disease that affects millions of women in North America. It is believed to develop as a result of dysfunction in the protective epithelial layer lining the bladder. TTI-1612, a locally delivered recombinant growth factor, is being developed to correct this dysfunction and restore the bladder epithelium to a normal, healthy state. Working with a premier advisory group of leading urologists, Trillium is in the final stages of completing the preclinical safety studies required for testing in humans and plans to submit a clinical trial application later this year.

www.trilliumtherapeutics.com